ORGS Share Price | Orgenesis, Inc. Stock Analysis & Recommendation

Q: How big is Orgenesis, Inc.?

Market Cap: As of Jun 18, Orgenesis, Inc. has a market capitalization of 9.98 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Orgenesis, Inc. reported net sales of 0.91 million and a net profit of -35.27 million.Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -20.98 million and total assets of 14.55 million.

Q: What does Orgenesis, Inc. do?

Overview:Orgenesis, Inc. is a biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, focused on developing, manufacturing, and processing technologies and services in the cell and gene therapy sector.Financial Snapshot:Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) Most recent Net Profit: -9 Million (Quarterly Results - Sep 2024) Market cap: USD 9.98 Million (Micro Cap) Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.60 Return on Equity: 121.55% Price to Book: -0.42 Contact Details:Address: 20271 Goldenrod Ln, Germantown MD: 20876-4064 Tel: 1 480 6596404 Website: https://www.orgenesis.com/

Q: Who are in the management team of Orgenesis, Inc.?

As of March 2022, the management team of Orgenesis, Inc. includes Ms. Vered Caplan, who serves as the Chairperson of the Board of Directors and Chief Executive Officer. The Board of Directors also comprises several independent directors: Mr. Yaron Adler, Mr. Ashish Nanda, Mr. Mario Philips, Dr. David Sidransky, and Mr. Guy Yachin.

Q: Is Orgenesis, Inc. overvalued or undervalued?

As of 9 February 2024, the valuation grade for Orgenesis, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a price-to-book value of -0.42 and an EV to EBITDA ratio of -1.01. Furthermore, the EV to Sales ratio stands at 24.38, which is excessively high compared to industry norms.In comparison with peers, Orgenesis, Inc. shows a stark contrast to Catalyst Biosciences, Inc., which is deemed expensive with a P/E ratio of 90.02, while other peers like Forte Biosciences, Inc. and Senti Biosciences, Inc. also do not qualify with negative valuation metrics. The company's recent stock performance has been dismal, with a 1-year return of -71.41%, significantly underperforming the S&P 500's 10.26% return in the same period. Overall, Orgenesis, Inc. is overvalued based on its current financial ratios and peer comparisons.

Q: Is Orgenesis, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Orgenesis, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend, while the monthly MACD shows a mildly bullish signal, suggesting some potential for recovery. The Bollinger Bands are bearish across both weekly and monthly time frames. Additionally, the On-Balance Volume (OBV) is mildly bearish on both weekly and monthly charts.In terms of performance, Orgenesis has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -97.30% compared to the S&P 500's 12.22%, and a one-year return of -99.06% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

421

Shareholding (Dec 2024)

FII

0.14%

Held by 7 FIIs

DII

97.18%

Held by 3 DIIs

Promoter

0.00%

How big is Orgenesis, Inc.?

22-Jun-2025

As of Jun 18, Orgenesis, Inc. has a market capitalization of 9.98 million, with net sales of 0.91 million and a net profit of -35.27 million over the last four quarters. The company reported shareholder's funds of -20.98 million and total assets of 14.55 million as of Dec 23.

View full answer

What does Orgenesis, Inc. do?

22-Jun-2025

Orgenesis, Inc. is a biopharmaceutical company specializing in cell and gene therapy technologies and services. As of September 2024, it reported net sales of $0 million and a net loss of $9 million, with a market cap of $9.98 million.

View full answer

Who are in the management team of Orgenesis, Inc.?

22-Jun-2025

As of March 2022, the management team of Orgenesis, Inc. is led by Ms. Vered Caplan as Chairperson and CEO, alongside independent directors Mr. Yaron Adler, Mr. Ashish Nanda, Mr. Mario Philips, Dr. David Sidransky, and Mr. Guy Yachin.

View full answer

Is Orgenesis, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Orgenesis, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics and a 1-year return of -71.41%, significantly underperforming its peers and the S&P 500.

View full answer

Is Orgenesis, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Orgenesis, Inc. is in a mildly bearish trend, with bearish indicators from the MACD, KST, and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -97.30%.

View full answer

Compare Orgenesis, Inc. with Similar Stocks

NeuroBo Pharmaceuticals, Inc.22nd Century Group, Inc.Catalyst Biosciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.60

Return on Equity

121.55%

Price to Book

-0.08

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Dec 2024)

Net Profit:

-20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

299.33%

6 Months

-40.1%

1 Year

-76.04%

2 Years

-87.85%

3 Years

-47.91%

4 Years

-98.24%

5 Years

-98.87%

Orgenesis, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-50.40%

EBIT Growth (5y)

-0.69%

EBIT to Interest (avg)

-29.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.60

Sales to Capital Employed (avg)

0.76

Tax Ratio

0.24%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.57%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.08

EV to EBIT

-0.63

EV to EBITDA

-0.68

EV to Capital Employed

-1.70

EV to Sales

16.24

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2024

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (2.68%)

Foreign Institutions

Held by 7 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is 0.00% vs 50.00% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2024 is -119.35% vs 1.06% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.00",
          "val2": "-7.10",
          "chgp": "29.58%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.00",
          "chgp": "30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.50",
          "val2": "-0.80",
          "chgp": "-1,587.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.40",
          "val2": "-9.30",
          "chgp": "-119.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-18,093.00%",
          "val2": "-21,962.50%",
          "chgp": "386.95%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 100.00% vs -98.61% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 24.50% vs -431.97% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "0.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.90",
          "val2": "-53.30",
          "chgp": "55.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.70",
          "val2": "2.20",
          "chgp": "68.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-19.00",
          "val2": "-1.00",
          "chgp": "-1,800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-49.00",
          "val2": "-64.90",
          "chgp": "24.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-25,135.30%",
          "val2": "-103,567.90%",
          "chgp": "7,843.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ

Dec'24

Sep'24

Change(%)

Net Sales

0.30

Operating Profit (PBDIT) excl Other Income

-5.00

-7.10

29.58%

Interest

1.30

1.00

30.00%

Exceptional Items

-13.50

-0.80

-1,587.50%

Consolidate Net Profit

-20.40

-9.30

-119.35%

Operating Profit Margin (Excl OI)

-18,093.00%

-21,962.50%

386.95%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2024 is 0.00% vs 50.00% in Sep 2024

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2024 is -119.35% vs 1.06% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1.00

0.50

100.00%

Operating Profit (PBDIT) excl Other Income

-23.90

-53.30

55.16%

Interest

3.70

2.20

68.18%

Exceptional Items

-19.00

-1.00

-1,800.00%

Consolidate Net Profit

-49.00

-64.90

24.50%

Operating Profit Margin (Excl OI)

-25,135.30%

-103,567.90%

7,843.26%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 100.00% vs -98.61% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 24.50% vs -431.97% in Dec 2023

All Annual Results

Company CV

About Orgenesis, Inc.

Orgenesis, Inc.

Pharmaceuticals & Biotechnology

Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.

Company Coordinates

Company Details

20271 Goldenrod Ln , GERMANTOWN MD : 20876-4064

Tel: 1 480 6596404

https://www.orgenesis.com/

Registrar Details